Background: The Philippines has a burden of drug-resistanttuberculosis
(DR-TB). One of the key challenges in the programmatic management of DR-TB
(PMDT) is the high rate of loss to follow-up (38% in the 2010 cohort). An
urgent need for a shorter, more tolerable, less expensive treatment regimen
exists. The aim of the operational study is to determine the efficacy and
safety of the short treatment regimen among drug resistant TB.Methods: This is a prospective single-arm cohort study evaluating the effectiveness
and safety of a shorter 9 - 11-month treatment regimen (9MTR) for rifampicin-resistant/multi-drug
resistant TB (RR/MDR-TB) in 10 PMDT facilities. All eligible consenting adult patients with rifampicin-resistant TBwere enrolled and received the standardized 9-month treatment regimen (9MTR),
including injectables, with a follow-up after 12 months of treatment
completion. Results:
References
[1]
World Health Organization (2017) Global Tuberculosis Report 2017. WHO, Geneva. http://www.who.int/tb/publications/global_report/en/
[2]
World Health Organization (2019) Global Tuberculosis Report 2019. WHO, Geneva. https://www.who.int/tb/publications/global_report/en/
[3]
Department of Health (2018) Third National Drug Resistance Survey on Tuberculosis in the Philippines, Technical Report. Department of Health, National TB Control Program, Infectious Diseases Office, Manila.
[4]
Tupasi, T.E., Garfin, A.M.G., Kurbatova, E.V., et al. (2016) Factors Associated with Loss to Follow up during Treatment for MDR-TB, the Philippines 2012-2014. Emerging Infectious Diseases, 22, 491-502. https://doi.org/10.3201/eid2203.151788
[5]
Philippines Department of Health (2015) National Tuberculosis Control Program (Unpublished) 2015 Accomplishment Report. Philippines Department of Health, Manila.
[6]
U.S. Department of Health and Human Services (2010) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf
[7]
World Health Organization (2016) WHO Treatment Guidelines for Drug-Resistant Tuberculosis. WHO, Geneva. http://apps.who.int/iris/bitstream/handle/10665/250125/9789241549639-eng.pdf
[8]
Falzon, D., Mirzayev, F., Wares, F., et al. (2015) Multidrug-Resistant Tuberculosis around the World: What Progress Has Been Made? European Respiratory Journal, 45, 150-160. https://doi.org/10.1183/09031936.00101814
[9]
Van Deun, A., Maug, A.K.J., Salim, A.H., et al. (2010) Short, Highly Effective and Inexpensive Standardized Treatment of Multidrug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 182, 684-692. https://doi.org/10.1164/rccm.201001-0077OC
[10]
Chang, K.C., Leung, C.C., Yew, W.W., et al. (2012) Pyrazinamide May Improve Fluoroquinolone-Based Treatment of Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 56, 5465-5475. https://doi.org/10.1128/AAC.01300-12
[11]
Nagaraja, C., Shashibhushan, B.L., Asif, M., Manjunath, P.H. and Sagar, C. (2012) Pattern of Drug-Resistance and Treatment Outcome in Multidrug-Resistant Pulmonary Tuberculosis. The Indian Journal of Chest Diseases and Allied Sciences, 54, 23-26.
[12]
Grosset, J.H., Tyagi, S., Almeida, D.V., et al. (2013) Assessment of Clofazimine Activity in a Second-Line Regimen for Tuberculosis in Mice. American Journal of Respiratory and Critical Care Medicine, 188, 608-612. https://doi.org/10.1164/rccm.201304-0753OC
[13]
Holtz, T.H., Sternberg, M., Kammerer, S., et al. (2006) Time to Sputum Culture Conversion in Multidrug-Resistant Tuberculosis: Predictors and Relationship to Treatment Outcome. Annals of Internal Medicine, 144, 650-659. https://doi.org/10.7326/0003-4819-144-9-200605020-00008
[14]
De Jaget, P. and Van Altena, R. (2002) Hearing Loss and Nephrotoxicity in Long-Term Aminoglycoside Treatment in Patients with Tuberculosis. The International Journal of Tuberculosis and Lung Disease, 6, 622-627.
[15]
Duggal, P. and Sarkar, M. (2007) Audiologic Monitoring of the Multi-Drug Resistant Tuberculosis Patients on Aminoglycoside Treatment with Long Term Follow-Up. BMC Ear, Nose and Throat Disorders, 7, Article No. 5. https://doi.org/10.1186/1472-6815-7-5
[16]
Brumett, R.E. and Fox, K.E. (1989) Aminoglycoside-Induced Hearing Loss in Humans. Antimicrobial Agents and Chemotherapy, 33, 797-800. https://doi.org/10.1128/AAC.33.6.797
[17]
Nadol Jr., J.B. (1993) Medical Progress: Hearing Loss. The New England Journal of Medicine, 329, 1092-1102. https://doi.org/10.1056/NEJM199310073291507
[18]
Tan, K.H.V., Mulheran, M., Knox, A.J. and Smyth, A.R. (2003) Aminoglycoside Prescribing and Surveillance in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 167, 819-823. https://doi.org/10.1164/rccm.200109-012CC
[19]
Selimoglu, F. (2007) Aminoglycoside-Induced Ototoxicity. Current Pharmaceutical Design, 13, 119-126. https://doi.org/10.2174/138161207779313731
[20]
World Health Organization (2015) Global Tuberculosis Report 2015. WHO, Geneva.
[21]
Philippines Department of Health (2000) National Tuberculosis Control Program (Unpublished) 2000 Accomplishment Report. Philippines Department of Health, Manila.
[22]
Trebucq, A., Schwoebel, V., Kashongwe, Z., et al. (2017) Treatment Outcome with a Short Multi-Drug-Resistant Tuberculosis Regimen in Nine African Countries. The International Journal of Tuberculosis and Lung Disease, 22, 17-25. https://doi.org/10.5588/ijtld.17.0498
[23]
Nunn, A.J., Phillips, P.P.J., Meredith, S.K., et al. (2019) A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. The New England Journal of Medicine, 380, 1201-1213. https://doi.org/10.1056/NEJMoa1811867
